1. 2023
  2. MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

    Eleveld, T. F., Vernooij, L., Schild, L., Koopmans, B., Alles, L. K., Ebus, M. E., Dandis, R., van Tinteren, H., Caron, H. N., Koster, J., van Noesel, M. M., Tytgat, G. A. M., Eising, S., Versteeg, R., Dolman, M. E. M. & Molenaar, J. J., 2023, In: Frontiers in oncology. 13, 1130034.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. 2022
  4. A Common Genomic Denominator for Neuroblastoma and Differentiated Thyroid Carcinoma? A Case Series in Children

    Clement, S. C., Koster, J., Kuiper, R. P., Tytgat, G. A. M., Ebus, M. E., Schild, L., Gilissen, C., Zwijnenburg, D. A., Versteeg, R., Molenaar, J. J. & van Santen, H. M., 1 Jul 2022, In: Clinical oncology (Royal College of Radiologists (Great Britain)). 34, 7, p. e318-e319

    Research output: Contribution to journalComment/Letter to the editorAcademic

  5. 2021
  6. Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma

    van den Boogaard, M. L., Oka, R., Hakkert, A., Schild, L., Ebus, M. E., van Gerven, M. R., Zwijnenburg, D. A., Molenaar, P., Hoyng, L. L., Dolman, E. M. M., Essing, A. H. W., Koopmans, B., Helleday, T., Drost, J., van Boxtel, R., Versteeg, R., Koster, J. & Molenaar, J. J., 7 Sep 2021, In: Proceedings of the National Academy of Sciences of the United States of America. 118, 36, e2007898118.

    Research output: Contribution to journalArticleAcademicpeer-review

  7. 2018
  8. RaS–MAPK pathway-driven tumor progression is associated with loss of CIC and other genomic aberrations in neuroblastoma

    Eleveld, T. F., Schild, L., Koster, J., Zwijnenburg, D. A., Alles, L. K., Ebus, M. E., Volckmann, R., Tijtgat, G. A., van Sluis, P., Versteeg, R. & Molenaar, J. J., 2018, In: Cancer research. 78, 21, p. 6297-6307

    Research output: Contribution to journalArticleAcademicpeer-review

  9. 2017
  10. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity

    Bate-Eya, L. T., Gierman, H. J., Ebus, M. E., Koster, J., Caron, H. N., Versteeg, R., Dolman, M. E. M. & Molenaar, J. J., 2017, In: European journal of cancer (Oxford, England. 75, p. 63-72

    Research output: Contribution to journalArticleAcademicpeer-review

  11. 2015
  12. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

    Dolman, M. E. M., Poon, E., Ebus, M. E., den Hartog, I. J. M., van Noesel, C. J. M., Jamin, Y., Hallsworth, A., Robinson, S. P., Petrie, K., Sparidans, R. W., Kok, R. J., Versteeg, R., Caron, H. N., Chesler, L. & Molenaar, J. J., 2015, In: Clinical cancer research. 21, 22, p. 5100-5109

    Research output: Contribution to journalArticleAcademicpeer-review

  13. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

    Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Daage, L. C., Diskin, S. J., Schild, L., Bentahar, N. B., Bellini, A., Chicard, M., Lapouble, E., Combaret, V., Legoix-Né, P., Michon, J., Pugh, T. J., Hart, L. S., Rader, J., Attiyeh, E. F., Wei, J. S., Zhang, S., & 26 othersNaranjo, A., Gastier-Foster, J. M., Hogarty, M. D., Asgharzadeh, S., Smith, M. A., Guidry Auvil, J. M., Watkins, T. B. K., Zwijnenburg, D. A., Ebus, M. E., van Sluis, P., Hakkert, A., van Wezel, E., van der Schoot, C. E., Westerhout, E. M., Schulte, J. H., Tytgat, G. A., Dolman, M. E. M., Janoueix-Lerosey, I., Gerhard, D. S., Caron, H. N., Delattre, O., Khan, J., Versteeg, R., Schleiermacher, G., Molenaar, J. J. & Maris, J. M., 2015, In: Nature genetics. 47, 8, p. 864-871

    Research output: Contribution to journalArticleAcademicpeer-review

  14. 2014
  15. Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours

    Bate-Eya, L. T., Ebus, M. E., Koster, J., den Hartog, I. J. M., Zwijnenburg, D. A., Schild, L., van der Ploeg, I., Dolman, M. E. M., Caron, H. N., Versteeg, R. & Molenaar, J. J., 2014, In: European journal of cancer (Oxford, England. 50, 3, p. 628-637

    Research output: Contribution to journalArticleAcademicpeer-review

  16. 2013
  17. Targeted Drug Development in Pediatric Cancer Despite a Low Frequency of Tumor Driving Mutations

    Molenaar, J. J., Koster, J., Ebus, M., Zwijnenburg, D. A., van Sluis, P., Lamers, F., Schild, L., van der Ploeg, I., Caron, H. N. & Versteeg, R., 2013, In: Annals of oncology. 24, p. i7

    Research output: Contribution to journalArticleAcademicpeer-review

Previous 1 2 Next

ID: 53917